ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0138 • ACR Convergence 2025

    Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis

    Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

    Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE).…
  • Abstract Number: 0021 • ACR Convergence 2025

    DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies

    Antonio Julià1, Yolanda Guillén2, Paloma Vela Casasempere3, Antonio Fernández Nebro4, Carlos Marras5, Santos Castañeda6, Jaime Calvo Alén7, Jesús Tornero Molina8, Juan Cañete9, Eugeni Domènech10, Javier Gisbert11, Jose M. Carrascosa12, Eduardo Fonseca13, Luis Bujanda Fernández De pierola14, Valle García Sánchez15, Britta Siegmund16, Giampiero Girolomoni17, Holger Heyn18, Laura Jiménez Gracia18, Pere Santamaria19, Edgar Angelats20, Richard Myers21, Sergio H. Martínez Mateu2, Juan Ángel Patiño Galindo2, Ernest Choy22 and Sara Marsal1, 1Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, 2IMIDomics, Barcelona, Spain, 3Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain, 4Hospital Regional Universitario Carlos Haya, Rheumatology, Málaga, Spain, 5Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Spain, 6Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 7Hospital Universitario de Araba, Rheumatology, Vitoria, Spain, 8Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain, 9Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 11Hospital Universitario La Princesa, Rheumatology, Madrid, Spain, 12Hospital Universitari Germans Trias i Pujol, Dermatology, Badalona, Spain, 13Complejo Hospitalario Universitario de A Coruña, Dermatology, A Coruña, Spain, 14Hospital Universitario de Donostia, Gastroenterology, San Sebastián, Spain, 15Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, 16Charité-Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany, 17University of Verona, Dermatology, Verona, Spain, 18Centre for Genomic Regulation (CNAG-CRG), Barcelona, Spain, 19Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelonoa, Spain, 20Hospital Clínic-IDIBAPS, Barcelona, Spain, 21HudsonAlpha Institute for Biotechnology, Huntsville, AL, 22Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom

    Background/Purpose: Targeted therapies have revolutionized the management of immune-mediated inflammatory diseases (IMIDs), however, there is a substantial number of patients who respond poorly to a…
  • Abstract Number: 0194 • ACR Convergence 2025

    Evaluation of a Home-based Therapeutics Service: Feasibility, Patient and Caregiver Experience, and Cost

    Xiaohui Xin, Andrea Low, Sow Ling Yee, Miao Miao Liu, Christina Tan, Daphne Ng and Siaw Ing Yeo, Singapore General Hospital, Singapore, Singapore

    Background/Purpose: The home-based therapeutics service (HTS) by a community nurse is part of an ongoing larger initiative—Community Therapeutics Programme (CTP)—spearheaded by the Rheumatology and Immunology…
  • Abstract Number: 0032 • ACR Convergence 2025

    Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease

    Kumar Thurimella1, Ahmed Mohamed2, Chenhao Li3, Tommi Vatanen4, Daniel Graham3, Roisin Owens5, Sabina Leanti La Rosa6, Damian Plichta3, Sergio Bacallado5 and Ramnik Xavier7, 1University of Colorado School of Medicine, Aurora, CO, 2Broad Institute, Boston, 3Broad Institute, Cambridge, MA, 4University of Helsinki, Helsinki, Finland, 5University of Cambridge, Cambridge, United Kingdom, 6NMBU, As, Norway, 7Harvard Medical School, Boston, MA

    Background/Purpose: Uncharacterized microbial enzymes in metagenomics are difficult to annotate, especially in fibrosis-prone conditions like IgG4-related disease (IgG4-RD) and Crohn’s disease (CD), where microbial carbohydrate…
  • Abstract Number: 0002 • ACR Convergence 2025

    KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases

    Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA

    Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
  • Abstract Number: 0026 • ACR Convergence 2025

    Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis

    Bilgesu Safak Tümerdem1, Yi-Nan Li2, Tim Filla3, Rolf Schröder4, Anna Brunn5, Alexandru Micu6, Ayla Nadja Stuetz1, Laura-Marie Lahu6, Aleix Rius Rigau7, Christina Bergmann8, Alexandru-Emil Matei9, Jörg Distler10 and Andrea-Hermina Györfi11, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 2University Hospital of Düsseldorf, Düsseldorf, Germany, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 4Institute of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Institute of Neuropathology, Heinrich-Heine University, University Hospital of Düsseldorf, Düsseldorf, Germany, 6Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, 7Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 8Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 9Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 10University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 11Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany

    Background/Purpose: Immune-mediated inflammatory myopathies (IIMs) are a heterogeneous group of diseases characterized by chronic inflammation, damage and impaired regeneration of the skeletal muscle leading to…
  • Abstract Number: 0073 • ACR Convergence 2025

    HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis

    S. Janna Bashar1, Courtney Myhr1, Adam Titi1, Zihao Zheng1 and Miriam Shelef2, 1University of Wisconsin-Madison, Madison, 2University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross-reactive binding to many antigens containing short motifs, or more private with…
  • Abstract Number: 0116 • ACR Convergence 2025

    Cerebral small vessel disease in antiphospholipid syndrome: subtypes and total burden of cSVD on MRI

    Chun Li1, Jianping Guo2, Yangyi Fan1, Yu Kang1 and Xiaodan Hu1, 1Peking University People's Hospital, Beijing, China (People's Republic), 2Peking University People's Hospital, Beijing, Beijing, China

    Background/Purpose: Cerebrovascular diseases are common and severe neurological complications in antiphospholipid syndrome (APS). However, few studies focused on cerebral small vessel disease (cSVD) in APS.…
  • Abstract Number: 0124 • ACR Convergence 2025

    Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome

    Haoyu Pan1, Shiyan Gu1, Xiaohan Wei2, Yuying Fan1, Jinyi Qian1, Shuyi Yu1 and Hui Shi3, 1Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), 2Shanghai JiaoTong University, Shanghai, China (People's Republic), 3Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)

    Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
  • Abstract Number: 0066 • ACR Convergence 2025

    RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.

    Yidan Wang1, Samuel Dowling2, Jessica Maciuch2, Vanessa Manada De Lobos2, Meghan Mayer2, Kainat Mian1, Tyler Therron3, Hadijat Makinde1, Carla Marie Cuda1, Deborah Rachelle Winter4 and Harris R Perlman1, 1Northwestern University, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern Feinberg School of Medicine, Chicago, IL, 4Northwestern University, Skokie, IL

    Background/Purpose: Tissue-resident monocyte-lineage cell (TRMC) are an extravascular population distinct from circulating monocytes and synovial macrophages and are critical for the development of inflammatory arthritis.…
  • Abstract Number: 0243 • ACR Convergence 2025

    Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain

    Carmen Lasa Teja1, Laura Muñoz-Llopis2, Diana Prieto-Peña3, Isla Morante Bolado4, José Luis Martín-Varillas5, Nerea Paz-Gandiaga6 and Ricardo Blanco7, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 3Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, 4Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, 5Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, 6Rheumatology, Hospital Comarcal de Laredo, Laredo, Spain., Santander, 7Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Systemic autoinflammatory diseases (SAIDs) are rare disorders characterized by recurrent episodes of fever, serositis, gastrointestinal symptoms, arthritis, and/or skin lesions. In adult-onset SAIDs, clinical…
  • Abstract Number: 0181 • ACR Convergence 2025

    Launch of the National Tele-Rheumatology Program (NTRP) to Expand Rheumatology Care to Rural Veterans

    Cherish Wilson1, Catherine Nasrallah2, Gary Tarasovsky3, Alicia Hamblin4, Asia Williams5, Broderick Flynn5, Bernard Ng6 and gabriela Schmajuk7, 1UCSF / SFVA, San Francisco, CA, 2University of California San Francisco (UCSF), San Francisco, CA, 3SFVA, San Francisco, 4UCSF, San Francisco, CA, 5Lexington VA, Lexington, 6Lexington VA, University of Washington, Seattle, 7University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA

    Background/Purpose: Given the nationwide shortage of rheumatologists, particularly in rural areas, many Veterans Affairs (VA) facilities have struggled to hire or retain specialists, resulting in…
  • Abstract Number: 0252 • ACR Convergence 2025

    Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH

    María Paula Carrillo1, Juan Esteban Bedoya-Loaiza1, Claudia Ibáñez-Antequera1, Laura Gallego1, Alejandro Escobar1, Adriana Rojas-Villarraga2 and Jairo Cajamarca-Baron3, 1Fundacion universitaria de ciencias de la salud, Bogota, Distrito Capital de Bogota, Colombia, 2Fundacion Universitaria de Ciencias de la salud, Bogotá, Distrito Capital de Bogota, Colombia, 3Fundacion universitaria de ciencia de la Salud, Bogota, Distrito Capital de Bogota, Colombia

    Background/Purpose: Nailfold capillaroscopy is a fundamental tool in rheumatology for assessing capillary morphology, allowing the differentiation between primary and secondary Raynaud’s phenomenon, identifying risks associated…
  • Abstract Number: 0244 • ACR Convergence 2025

    Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus

    Carmen Lasa Teja1, Javier Loricera2, Marcos López-Hoyos3, Carmen Bejerano-Herreria4, Andrea Estébanez5, Mireia Sanmartin Martínez6, Marta González-Fernández7, Ivan Ferraz Amaro8 and Ricardo Blanco9, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 3Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 4Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 5Department of Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain, Valencia, Spain, 6Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 7Basurto University Hospital, Bilbao, Pais Vasco, Spain, 8Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 9Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Anifrolumab is a human monoclonal antibody targeting the type I interferon receptor, approved for the treatment of systemic lupus erythematosus (SLE), with demonstrated efficacy…
  • Abstract Number: 0158 • ACR Convergence 2025

    Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)

    Lesley Jackson1, jerrod anzalone2, Rahima Begum3, Fazlur Rahman1, Namrata Singh4, Londyn Robinson5, Kaleb Michaud2, Kenneth Saag6, Jasvinder Singh7, Rena Patel1 and Maria I. ("Maio") Danila8, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Nebraska Medical Center, Omaha, NE, 3University of Alabama at Birmingham, Birmingham, 4University of Washington, Bellevue, WA, 5University of Washington, Seattle, WA, 6The University of Alabama at Birmingham, Birmingham, AL, 7Baylor College of Medicine, Houston, TX, 8University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: People with autoimmune rheumatic diseases (AIRD) are at higher risk for serious complications and poor outcomes from COVID-19 infection. Data is lacking on outcomes…
  • « Previous Page
  • 1
  • …
  • 140
  • 141
  • 142
  • 143
  • 144
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology